Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087877 · ClinicalTrials.gov registry record · NA
Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor
A NA study, sponsored by DexCom.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT03087877: Completed NA study, sponsored by DexCom.
NCT03087877 is a NA study that has completed, run by DexCom. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03087877, a NA study, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in preventing acetaminophen's interference effect on glucose sensing.
Primary Outcome
Bias of sensor to reference measurement pre and post acetaminophen administration
Interventions
- DEVICE Acetaminophen Challenge (G6 CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2017-03-04 |
| Phase | NA |
What the finished NCT03087877 record still lists
NCT03087877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Acetaminophen Challenge (G6 CGM) is the first listed.
NCT03087877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03087877 about?
NCT03087877 is a clinical study titled "Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor". The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in preventing acetaminophen's interference effect on glucose sensing.
What is the current status of trial NCT03087877?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2017-02-03. Estimated completion is 2017-03-04.
What interventions are being tested in trial NCT03087877?
The interventions under investigation include: Acetaminophen Challenge (G6 CGM) (DEVICE).
Who is sponsoring clinical trial NCT03087877?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03087877's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI